Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
8.41
-0.08 (-0.94%)
Nov 4, 2024, 4:00 PM EST - Market closed
Amneal Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -174.62 | -83.99 | -129.99 | 10.62 | 91.06 | -361.92 | Upgrade
|
| Depreciation & Amortization | 225.24 | 229.4 | 240.18 | 233.41 | 235.39 | 243.63 | Upgrade
|
| Other Amortization | 4.88 | 8.18 | 8.6 | 9.2 | 8.68 | 6.48 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | - | -0.12 | -7.26 | Upgrade
|
| Asset Writedown & Restructuring Costs | 66.57 | 66.93 | 24.08 | 28.55 | 36.72 | 185.24 | Upgrade
|
| Stock-Based Compensation | 26.11 | 26.82 | 31.85 | 28.41 | 20.75 | 21.68 | Upgrade
|
| Other Operating Activities | 154 | 145.42 | -49.67 | 65.21 | 47.85 | 34.07 | Upgrade
|
| Change in Accounts Receivable | -96.53 | 126.29 | -79.72 | -23.62 | 16.79 | -132.73 | Upgrade
|
| Change in Inventory | -101.1 | -126.18 | -102.4 | -49.02 | -113.78 | -20.39 | Upgrade
|
| Change in Accounts Payable | 135.34 | -94.45 | 109.57 | -43.93 | 0.31 | -10.26 | Upgrade
|
| Change in Other Net Operating Assets | 12.56 | 47.15 | 12.6 | -17.03 | 35.37 | 43.16 | Upgrade
|
| Operating Cash Flow | 252.46 | 345.58 | 65.1 | 241.82 | 379 | 1.71 | Upgrade
|
| Operating Cash Flow Growth | 27.09% | 430.84% | -73.08% | -36.20% | 22128.80% | -99.32% | Upgrade
|
| Capital Expenditures | -45.03 | -46.8 | -48.8 | -50.94 | -61.84 | -47.18 | Upgrade
|
| Cash Acquisitions | - | - | -84.71 | -146.54 | -251.36 | - | Upgrade
|
| Divestitures | 4.99 | - | - | - | - | 34.83 | Upgrade
|
| Sale (Purchase) of Intangibles | -31.35 | -22.39 | -41.8 | -1.7 | -4.35 | -50.25 | Upgrade
|
| Other Investing Activities | - | - | 1 | 5 | - | 43.02 | Upgrade
|
| Investing Cash Flow | -71.39 | -69.19 | -174.31 | -194.18 | -317.55 | -19.58 | Upgrade
|
| Short-Term Debt Issued | - | 219 | 85 | - | - | - | Upgrade
|
| Long-Term Debt Issued | - | 217.73 | - | - | 180 | - | Upgrade
|
| Total Debt Issued | 384.73 | 436.73 | 85 | - | 180 | - | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -1 | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -414.08 | -123.27 | -78.18 | -37.01 | -29.27 | Upgrade
|
| Total Debt Repaid | -416.89 | -414.08 | -123.27 | -79.18 | -37.01 | -29.27 | Upgrade
|
| Net Debt Issued (Repaid) | -32.16 | 22.65 | -38.27 | -79.18 | 142.99 | -29.27 | Upgrade
|
| Issuance of Common Stock | 0.84 | 0.45 | 0.66 | 0.85 | 0.32 | 1.4 | Upgrade
|
| Repurchase of Common Stock | -7.72 | -2.38 | -3.57 | -2.66 | -0.86 | -0.93 | Upgrade
|
| Other Financing Activities | -206.62 | -233.3 | -65.44 | -57.13 | -10.64 | -17.04 | Upgrade
|
| Financing Cash Flow | -245.66 | -212.57 | -106.62 | -138.12 | 131.81 | -45.83 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.37 | 0.07 | -5.68 | 0.1 | 1.04 | -2.25 | Upgrade
|
| Net Cash Flow | -64.96 | 63.88 | -221.51 | -90.38 | 194.3 | -65.96 | Upgrade
|
| Free Cash Flow | 207.43 | 298.78 | 16.3 | 190.88 | 317.17 | -45.48 | Upgrade
|
| Free Cash Flow Growth | 41.00% | 1732.42% | -91.46% | -39.82% | - | - | Upgrade
|
| Free Cash Flow Margin | 7.98% | 12.48% | 0.74% | 9.12% | 15.92% | -2.80% | Upgrade
|
| Free Cash Flow Per Share | 0.82 | 1.70 | 0.11 | 1.26 | 2.13 | -0.34 | Upgrade
|
| Cash Interest Paid | 240.64 | 192.81 | 142.72 | 121.75 | 130.19 | 158.57 | Upgrade
|
| Cash Income Tax Paid | 8.79 | 2.5 | 12.65 | 15.56 | -100.14 | -10.26 | Upgrade
|
| Levered Free Cash Flow | 170.86 | 303.9 | 120.14 | 217.65 | 153.82 | 55.81 | Upgrade
|
| Unlevered Free Cash Flow | 317.15 | 427.36 | 210.53 | 293.65 | 236.39 | 154.46 | Upgrade
|
| Change in Net Working Capital | 77.29 | -70.71 | 95.92 | 50.9 | 44.6 | 5.47 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.